Table 2.
Treatment-related adverse events (maximum grade, all cycles).
| Adverse event | Any grade, No. (%) | Grade 3-4, No. (%) |
|---|---|---|
| Rash | 35 (76%) | 10 (22%) |
| Diarrhea | 35 (76%) | 6 (13%) |
| Nausea/vomiting | 27 (59%) | 4 (9%) |
| Fatigue | 26 (57%) | 3 (7%) |
| AST/ALT elevation | 22 (48%) | 4 (9%) |
| Anorexia | 15 (33%) | 0 (0%) |
| Anemia | 14 (30%) | 5 (11%) |
| Dysgeusia | 11 (24%) | 0 (0%) |
| Eye disorders1 | 9 (20%) | 0 (0%) |
| Pruritis | 9 (20%) | 0 (0%) |
| Hypertension | 8 (17%) | 6 (13%) |
| Thrombocytopenia | 5 (11%) | 1 (2%) |
| Leukopenia/neutropenia | 4 (9%) | 1 (2%) |
| Thromboembolic event2 | 4 (9%) | 3 (7%) |
| Elevated creatinine | 4 (9%) | 0 (0%) |
1
Including blurry vision, eye pain, floaters, and dry or watery eyes.
2
Including cerebrovascular event (1).